Mont-Saint-Guibert, Belgium, November 27, 2024, 6:00 PM CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in severe autoimmune and inflammatory diseases, announces that its subsidiary Medsenic has secured a new patent (B180218EP), which will be published on December 25, 2024, on the European Patent Office (EPO) website. The European patent application No. 18722530.5, filed on May 4, 2018, pertains to a “Method for treating multiple sclerosis using arsenic.”
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease that affects the brain, spinal cord, and optic nerves. It leads to the degradation of the protective sheath surrounding and nourishing neurons, which are essential for transmitting information between the brain and the rest of the body. In France, over 130,000 individuals are affected by MS, with 1 million cases in Europe and 2.8 million worldwide. To date, there is no cure for multiple sclerosis.
This key patent, specific to MS, granted by the EPO, aligns with BioSenic’s intellectual property strategy, which includes additional patent applications in other regions. These patents will support BioSenic's implementation of international clinical trials for autoimmune diseases with significant unmet medical needs. These trials aim to generate clinical data that will further enable market access approvals.
